Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
Aquestive Therapeutics (NASDAQ: AQST) has announced its participation in the upcoming Citizens Life Sciences Conference taking place from May 7-8, 2025, in New York City. The company's management team will conduct a fireside chat on May 8th at 10 am ET and will be available for one-on-one meetings with investors on the same day.
The fireside chat will be accessible via webcast on the company's website under the "Events and Presentations" page in the Investors section, with a replay available for 30 days after the event.
Aquestive Therapeutics (NASDAQ: AQST) ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference, che si terrà dal 7 all'8 maggio 2025 a New York City. Il team di gestione della società terrà una tavola rotonda informale il 8 maggio alle 10:00 ET e sarà disponibile per incontri individuali con gli investitori nello stesso giorno.
La tavola rotonda sarà accessibile tramite webcast sul sito web della società, nella sezione "Eventi e Presentazioni" della pagina Investitori, con la possibilità di rivederla per 30 giorni dopo l'evento.
Aquestive Therapeutics (NASDAQ: AQST) ha anunciado su participación en la próxima Citizens Life Sciences Conference, que se llevará a cabo del 7 al 8 de mayo de 2025 en la ciudad de Nueva York. El equipo directivo de la compañía realizará una charla informal el 8 de mayo a las 10 am ET y estará disponible para reuniones individuales con inversores ese mismo día.
La charla informal estará disponible vía webcast en el sitio web de la compañía en la página de "Eventos y Presentaciones" dentro de la sección para inversores, con una repetición disponible durante 30 días después del evento.
Aquestive Therapeutics (NASDAQ: AQST)가 2025년 5월 7일부터 8일까지 뉴욕시에서 열리는 Citizens Life Sciences Conference에 참여한다고 발표했습니다. 회사 경영진은 5월 8일 오전 10시 ET에 파이어사이드 챗을 진행하며, 같은 날 투자자들과 일대일 미팅도 진행할 예정입니다.
파이어사이드 챗은 회사 웹사이트의 투자자 섹션 내 "이벤트 및 발표" 페이지에서 웹캐스트로 시청할 수 있으며, 행사 종료 후 30일 동안 다시보기 가능합니다.
Aquestive Therapeutics (NASDAQ : AQST) a annoncé sa participation à la prochaine Citizens Life Sciences Conference qui se tiendra du 7 au 8 mai 2025 à New York. L'équipe de direction de l'entreprise animera une discussion informelle le 8 mai à 10h00 ET et sera disponible pour des rencontres individuelles avec les investisseurs le même jour.
La discussion informelle sera accessible en webcast sur le site internet de la société, dans la section "Événements et Présentations" de la rubrique Investisseurs, avec une rediffusion disponible pendant 30 jours après l'événement.
Aquestive Therapeutics (NASDAQ: AQST) hat seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference angekündigt, die vom 7. bis 8. Mai 2025 in New York City stattfindet. Das Management-Team des Unternehmens wird am 8. Mai um 10 Uhr ET ein informelles Gespräch führen und steht am selben Tag für Einzelgespräche mit Investoren zur Verfügung.
Das Gespräch wird als Webcast auf der Unternehmenswebsite unter der Seite "Events and Presentations" im Investor-Bereich verfügbar sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung abrufbar ist.
- None.
- None.
WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Citizens Life Sciences Conference from May 7-8 in New York City.
The Aquestive team will hold a fireside chat on May 8th at 10 am ET; management will also be hosting one-on-ones with investors that same day.
A webcast of the fireside chat will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by the Company’s licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatological conditions including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com
FAQ
When is Aquestive Therapeutics (AQST) presenting at the Citizens Life Sciences Conference 2025?
Where can I watch Aquestive Therapeutics' (AQST) Citizens Life Sciences Conference presentation?
Will Aquestive Therapeutics (AQST) management be available for meetings at the Citizens Life Sciences Conference?
How long will Aquestive Therapeutics' (AQST) conference presentation replay be available?
